No Data
No Data
BeiGene (06160.HK) issued 261.82 million shares under the share award scheme on April 30
BeiGene (06160.HK) announced that it will issue 261.82 million shares under the share award program on April 30, 2024.
BeiGene (06160.HK) issued 155,900 shares due to restricted share units
On May 2, GLONGHUI (06160.HK) issued an announcement. On April 30, 2024, 155,900 common shares will be issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene PD-1 inhibitor Baizean approved 13th application for indication in China
China National Drug Administration (NMPA) approves Baize'an (tirelizumab) as a new indication for gastric cancer, Beijing, April 30, 2024/4/2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235), a global cancer treatment innovation company, announced today that its PD-1 inhibitor baizean (tirelizumab) has been officially approved by China's National Drug Administration (China Drug Administration) in combination with fluorouracil and platinum chemotherapeutics For advanced local use, unresectable or metastatic stomach or stomach eating
BeiGene (06160.HK) issued 238,600 shares due to restricted share units
On April 30, GLONGHUI | BeiGene (06160.HK) issued an announcement. On April 29, 2024, 238,600 common shares were issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene (06160) issued approximately 121,000 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 28, 2024, due to a restricted share list granted under an equity plan...
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio?Vertiv Holdings Co (NYSE:VRT) increased 23.3% after it reported bet
No Data